U.S. Markets closed

Cullinan Oncology, Inc. (CGEM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.69+0.35 (+2.62%)
At close: 04:00PM EST
13.69 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.34
Bid13.70 x 1100
Ask14.20 x 900
Day's Range12.69 - 13.79
52 Week Range12.69 - 59.85
Avg. Volume289,246
Market Cap598.041M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.25
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment

    Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mo

  • GlobeNewswire

    Cullinan Oncology to Present at Upcoming Virtual Investor Conferences

    CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in January: 40th Annual J.P. Morgan Healthcare Conference Thursday, January 13 at 7:30 a.m. ET HC Wainwright BioConnect Conference Presentation available on-demand for registered conference attendees beginning Monday, January 10 at 7:00 a.m. ET A live webcast of the J.P. Morgan presentation will be available v

  • MarketWatch

    Cullinan Oncology stock shoots higher after lung cancer treatment granted BTD by FDA

    Shares of Cullinan Oncology Inc. shot up 15.2% in premarket trading Tuesday, after the biopharmaceutical company said its CLN-081 was granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration for the treatment of non-small cell lunch cancer. A BTD expedites the development and review of drugs for the treatment of serious conditions, in which preliminary clinical evidence indicates the drug may demonstrate substantial improvement over currently available therapies. "